SWOG clinical trial number
CTSU/NRG-GI004

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Closed
Phase
Abbreviated Title
COMMIT
Closed
09/02/2025
Participants
CTSU, ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Gastrointestinal Cancer
Symptom Control and Quality of Life

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2021

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)

M Overman;G Yothers;S Jacobs;H Sanoff;D Cohen;K Guthrie;NL Henry;P Ganz;ES Kopetz;P Lucas;CD Blanke;N Wolmark;H Hochster;T George;SMS Rocha Lima J Clin Oncol 39, 2021 (suppl 3; abstr TPS158); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), TIPS, poster

2020

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG-GI004/SWOG-S1610)

CMS Rocha Lima;G Yothers;SA Jacobs;H Sanoff;DJ Cohen;K Guthrie;NL Henry;P Ganz;ES Kopetz;PC Lucas;CJ Allegra;CD Blanke;N Wolmark;HS Hochster;TJ George;MJ Overman J Clin Oncol 38, 2020 (suppl 4; abstr TPS260); ASCO GI Cancers Symposium (January 23-25, 2020, San Francisco, CA)

2018

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/ bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer

J Lee;G Yothers;SA Jacobs;H Sanoff;D Cohen;K Guthrie;NL Henry;P Ganz;PC Lucas;C Allegra;C Blanke;N Wolmark;H Hochster;TJ George;M Overman J Clin Oncol 36, 2018 (suppl; abstr TPS3615); ASCO Annual Meeting (June 1-5, 2018, Chicago, IL), poster session

Other Clinical Trials

SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
Accrual
66%
Open
Phase
SWOG Clinical Trial Number
EAQ202

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Research Committee(s)
Symptom Control and Quality of Life
Activated
08/16/2021
Accrual
65%
Open
Phase